Consultant. Innovative medical diagnostics, novel biomarkers, digital health, medtech, and biotech. Prior McKinsey, industry executive, and stock analyst.
@DTWillingham Agreed. The same prompt (if it’s for a real task) will return different results, often quite different. And certainly OpenAI is always tinkering, obviating even reproducible approaches.
Payors, Labs Parsing State Biomarker Testing Laws to Better Understand Coverage Mandates. Laws passed in 14 states appear to require commercial payors to cover biomarker tests broadly that meet certain evidentiary criteria, but payors may have a... https://t.co/61t80Qg41n
@AppleHelix Agreed. How on earth would those studies be funded? Is there some "if, then;" whereby, the USPTO says if a study meets some particular endpoint that the patent is then automatically granted?
@JAMA_current Shape matters, not just AUC, in many cases more. Why are there no ROC curves shown? Also, the use of ROC curves, which are prevalence independent, ignores positive ("rule-in") and negative ("rule-out") predicitve values. Without those, AUCs, low or high, cannot really be judged.
#ChatGPT fatally flawed by propagating (expands?) scientific publication bias (#GPT-3 itself agrees a huge problem). Need severe warning, not just “I might be wrong.” Betting it leads to stronger status quo, less new knowledge. #retraction#publicationbias#reproducibilitycrisis
European Investment Bank Finances Innovative Diagnostics Developer #Numares Health with €20 Million
Numares develops precision multi-biomarker diagnostic tests for patients with chronic kidney, heart and liver disease.
https://t.co/LjBnUsdBkc
https://t.co/qYyU3Ifmww
#Numares and #MayoClinic deepen its collaboration for patient care in #metabolic & #inflammatory conditions as #Mayo invests in numares with a convertible equity investment.
Together, we work to create #NMR#metabolomic tests to help physicians better care for their patients.